Anteneh Tebeje
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anteneh Tebeje has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Anna Novikova
Department of Physiology and Biophysics, University of Illinois College of Medicine, University of Illinois Cancer Center, Chicago, Illinois, USA
1 shared publication - Christopher Solís
Department of Health, Nutrition, and Food Sciences, Florida State University, Tallahassee, Florida, United States of America,
1 shared publication - David Sept
Department of Biomedical Engineering, University of Michigan
1 shared publication - Frank M. Mason
Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
1 shared publication - Gina M. DeNicola
Department of Metabolism and Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
1 shared publication - Gregory Stephanopoulos
Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
1 shared publication
Latest Publications
- Open Access
- 23 May 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (13)
Drug screening in human physiologic medium identifies uric acid as an inhibitor of rigosertib efficacy
The nonphysiological nutrient levels found in traditional culture media have been shown to affect numerous aspects of cancer cell physiology, including how cells respond to certain therapeutic agents. Here, we comprehensively evaluated how physiological nutrient levels affect therapeutic response by performing drug screening in human plasma-like medium. We observed dramatic nutrient-dependent changes in sensitivity to a variety of FDA-approved and clinically trialed compounds, including rigosertib, an experimental cancer therapeutic that recently failed in phase III clinical trials. Mechanistically, we found that the ability of rigosertib to destabilize microtubules is strongly inhibited by the purine metabolism end product uric acid, which is uniquely abundant in humans relative to traditional in vitro and in vivo cancer models. These results demonstrate the broad and dramatic effects nutrient levels can have on drug response and how incorporation of human-specific physiological nutrient medium might help identify compounds whose efficacy could be influenced in humans.
- 23 May 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (13)
Open AccessDrug screening in human physiologic medium identifies uric acid as an inhibitor of rigosertib efficacy
The nonphysiological nutrient levels found in traditional culture media have been shown to affect numerous aspects of cancer cell physiology, including how cells respond to certain therapeutic agents. Here, we comprehensively evaluated how physiological nutrient levels affect therapeutic response by performing drug screening in human plasma-like medium. We observed dramatic nutrient-dependent changes in sensitivity to a variety of FDA-approved and clinically trialed compounds, including rigosertib, an experimental cancer therapeutic that recently failed in phase III clinical trials. Mechanistically, we found that the ability of rigosertib to destabilize microtubules is strongly inhibited by the purine metabolism end product uric acid, which is uniquely abundant in humans relative to traditional in vitro and in vivo cancer models. These results demonstrate the broad and dramatic effects nutrient levels can have on drug response and how incorporation of human-specific physiological nutrient medium might help identify compounds whose efficacy could be influenced in humans.